Skip to content
Menu

Rapport Therapeutics, Inc. RAPP

Full chart Compare
Set alert

Price alert · RAPP

All alert types
23.16 USD -0.43 (-1.82%)

Regular-session close

23.16 0.00 0.00%

After hours · Nov 20, 4:26 PM ET

23.00 Day range 23.83
22.50 52-week range 52.50
YTD
-23.67%
1 year
-13.74%

Fundamental scorecard

3 of 25 checks passed on RAPP’s reported financials

ValueGrowthProfitabilityHealthDividend

3of 25 checks passed

  • Value 0 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Value 0 of 5

  • Failed:P/E below its own 5-year median No profit over the last 12 months, so no P/E.
  • Failed:P/E under 20 No profit over the last 12 months, so no P/E.
  • No data:Price to sales below its own 5-year median Price to sales 68.6. Not enough data to decide.
  • No data:Price to book below its own 5-year median Price to book 3.5. Not enough data to decide.
  • Failed:Free cash flow yield above 4% Free cash flow of -121M is -8.8% of the market value.

Growth 0 of 5

  • No data:Revenue grew over the last year Not enough data to decide.
  • No data:Revenue grew more than 5% a year over five years Not enough data to decide.
  • Failed:Earnings per share grew over the last year EPS -3.16 against -2.26 in the 12 months before.
  • No data:Earnings per share grew more than 5% a year over five years Not enough data to decide.
  • No data:Analysts expect higher earnings per share over the next year No analyst estimate.

Profitability 0 of 5

  • Failed:Profitable over the last year Net income of -150M over the last 12 months.
  • No data:Profitable in each of the last five fiscal years Not enough data to decide.
  • Failed:Return on equity above 15% Return on equity of -33.3%.
  • No data:Net margin above its 5-year average Not enough data to decide.
  • Failed:Free cash flow is at least 80% of net income No profit over the last 12 months to compare with.

Financial health 3 of 5

  • Passed:Short-term assets cover short-term liabilities Short-term assets of 407M against short-term liabilities of 20.3M.
  • Passed:Short-term assets cover long-term liabilities Short-term assets of 407M against long-term liabilities of 7.07M.
  • Passed:Net debt under 40% of equity More cash than debt: 395M of cash against 9.39M of debt.
  • Failed:Operating cash flow covers at least 20% of debt Operating cash flow of -121M is -1286.9% of debt.
  • No data:Operating profit covers interest at least 3 times Not enough data to decide.

Dividend 0 of 5

  • Failed:Pays a dividend No dividend paid.
  • Failed:Yield above 1.5% No dividend paid.
  • Failed:Pays out under 75% of profit No dividend paid.
  • Failed:Covered by free cash flow No dividend paid.
  • Failed:Not cut in the last five fiscal years No dividend paid.

Mechanical checks on reported financials against fixed thresholds. They describe the numbers; they are not a recommendation to buy or sell.

Included in Essentials and up

Sign in to see Fair value

Discounted cash flow estimates against the price, and the P/E against its industry and sector.

Included in Essentials and up

Sign in to see Head count and owner earnings

Employees by annual report and the cash the business earns for its owners.

Included in Essentials and up

Sign in to see P/E against peers

The price to earnings ratio beside the closest competitors and their median.

Financial position

What RAPP owns and owes, as of Sep 30, 2026

Short term and long term

Balance sheet · 419M of assets

Debt, equity and cash by year

Now: 386M more cash than debt

Fiscal years, then the newest quarter. Cash includes short-term investments.

From the company’s SEC filings.

Included in Essentials and up

Sign in to see Cash flow and returns

How profit turns into free cash flow, and the returns on equity, assets and capital.

Financial health

Altman Z-Score

23.26 Safe zone

Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.

Piotroski F-Score

3 / 9 Weak

Nine pass/fail tests of profitability, leverage and efficiency.

Rating

C2 / 5 overall

  • DCF 2
  • Return on Equity 1
  • Return on Assets 1
  • Debt / Equity 4
  • P/E 1
  • P/B 2

Valuation

P/E -10.6×
P/S 0.0×
P/B 2.4×
P/FCF -13.4×
EV/EBITDA -9.2×
EV/Sales 0.0×
FCF Yield -7.5%

Profitability

Gross Margin 0.0%
Operating Margin 0.0%
Net Margin 0.0%
ROE -23.0%
ROIC -25.2%
ROA -21.8%

Growth (YoY)

Revenue 0.0%
Operating Income -50.6%
EPS (diluted) -33.6%
Free Cash Flow -31.0%

Financial Health

Current Ratio 26.2×
Quick Ratio 26.2×
Debt / Equity 0.0×
Net Debt / EBITDA 0.3×
Interest Coverage 0.0×

Dividends

Dividend Yield 0.0%
Payout Ratio 0.0%

Annual · latest fiscal year ends 2025-12-31